MSL
BEAM icon

Mackay Shields LLC’s Beam Therapeutics BEAM Stock Holding History

Mackay Shields LLC’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,600
Closed -$608K – 777
2021
Q1 		$608K Buy
+7,600
New +$723K ﹤0.01% 1149

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackay Shields LLC's BEAM Position: Q2 2021 in Review

Mackay Shields LLC sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 7,600 shares — an estimated $608K sold.

Mackay Shields LLC first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $608K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Mackay Shields LLC reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 7,600 Beam Therapeutics shares in Q2 2021, an estimated $608K.
  • Mackay Shields LLC first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
  • Mackay Shields LLC's Beam Therapeutics position peaked at $608K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.